Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
| US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(10 years from now) | |
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
| US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
| US11708333 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(10 years from now) | |
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(15 years from now) | |
| US11618733 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(15 years from now) | |
Orladeyo is owned by Biocryst.
Orladeyo contains Berotralstat Hydrochloride.
Orladeyo has a total of 8 drug patents out of which 0 drug patents have expired.
Orladeyo was authorised for market use on 03 December, 2020.
Orladeyo is available in capsule;oral dosage forms.
Orladeyo can be used as prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older.
Drug patent challenges can be filed against Orladeyo from 03 December, 2024.
The generics of Orladeyo are possible to be released after 01 November, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
Drugs and Companies using
BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date:
Market Authorisation Date:
03 December, 2020Treatment:
Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and olderDosage:
More Information on Dosage
ORLADEYO family patents
